Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.36−0.51 (-4.69%)
Close on Nov 13, 2026Market cap $595.04MP/E –Yield –
Climb Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Climb Bio's ebitda for the twelve months ending Sep 30, 2026 was -$66.46M. For fiscal 2025 it was -$67.79M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.79M | – |
| FY2024 | Dec 31, 2024 | -$82.02M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$16.70M | – |
| Q2 FY2026 | Jun 30, 2026 | -$15.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.73M | – |
See a number that looks wrong?